Dr. Levine Discusses a Combination Study in Endometrial Cancer

Douglas A. Levine, MD
Published: Wednesday, Apr 11, 2018



Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone's Perlmutter Cancer Center, discusses the randomized NRG Oncology Group 86P study for patients with endometrial cancer.

This was a phase III trial that randomized patients with advanced or recurrent endometrial cancer who had not received prior chemotherapy to 1 of 3 arms, either taxol, carboplatin, and bevacizumab (Avastin), taxol, carboplatin, and temsirolimus, or ixabepilone (Ixempra), carboplatin, and bevacizumab. The primary outcome was progression-free survival, which was compared with a historical control from the GOG-209 study.

Physicians are still trying to validate the data. There have not been a lot of studies that have investigated bevacizumab in endometrial cancer. According to Levine, it is important to find a study that has been completed and has collected tissue to confirm the biomarker of beta-catenin for patients treated with bevacizumab. Determining who will benefit from bevacizumab is an additional area that needs to be investigated further.
 


Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone's Perlmutter Cancer Center, discusses the randomized NRG Oncology Group 86P study for patients with endometrial cancer.

This was a phase III trial that randomized patients with advanced or recurrent endometrial cancer who had not received prior chemotherapy to 1 of 3 arms, either taxol, carboplatin, and bevacizumab (Avastin), taxol, carboplatin, and temsirolimus, or ixabepilone (Ixempra), carboplatin, and bevacizumab. The primary outcome was progression-free survival, which was compared with a historical control from the GOG-209 study.

Physicians are still trying to validate the data. There have not been a lot of studies that have investigated bevacizumab in endometrial cancer. According to Levine, it is important to find a study that has been completed and has collected tissue to confirm the biomarker of beta-catenin for patients treated with bevacizumab. Determining who will benefit from bevacizumab is an additional area that needs to be investigated further.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x